Synopsis: Gland Pharma shares surged 9% after strong Q3 FY26 results, driven by 42% QoQ PAT growth, robust revenue expansion, and improving margins. Strong execution in regulated markets and pipeline progress boosted investor confidence.
The shares of this company which is a leading generic injectables manufacturer, operating primarily on a B2B model with a strong global presence across 60-plus countries, including the US and Europe, had its shares in momentum today following the company reporting a 42% PAT growth with robust results and growth in several of its performance metrics
With the market cap of Rs 29,968 crore, the shares of Gland Pharma Ltd have gained about 9% and reached a high at Rs 1,849, compared to their previous day’s closing price of Rs 1,688.70. The shares are trading at a PE of 34.7, whereas its industry PE is at 29.
About the Q3 Result highlights
The revenue from operation for the company stood at Rs 1,695 crore when compared to Rs 1,384 crore in Q3 FY25, growing by about 22 per cent on a YoY basis and on a QoQ basis increasing by 14 per cent from Rs 1,487 crore in Q2 FY26.
The PAT grew by about 27 per cent on a YoY basis when you compare the Q3 FY26 profit at Rs 261 crore to Rs 205 crore in Q3 FY25 and on a QoQ basis has increased 42 per cent from Rs 184 crore in Q2 FY26.
Business highlights
The company is furthering its innovation-driven growth momentum with increased R&D expenses of Rs 650 million, contributing 5.4% to revenue in Q3 FY26, due to complex product development and an expanding regulatory filing pipeline.
With nine product launches in the US, an ongoing ANDA filing strategy for generic drug approvals with the US FDA, cumulatively filing 384 ANDAs, of which 331 are approved, and an expanding in-house complex injectables pipeline, the company is further enhancing its leadership position in the regulated markets and developing a strong product pipeline over the long term.
Growth visibility is also reinforced by 15 co-development partnerships for new products, an emerging Ready-to-Use portfolio of pre-mixed injectable products, addressing an estimated US market opportunity of $685 million, and programmes in drug-device combinations and contract manufacturing for oncology therapeutics.
Enhancements in pen and cartridge manufacturing capacity and development of GLP-1 drug delivery platforms for diabetes and obesity treatments are poised to drive the company’s growth momentum over the medium to long term, with significant commercialisation expected from FY28 onwards.
Management commentary
Mr Shyamakant Giri, Chief Executive Officer of Gland Pharma, said, “Performance of Q3 FY26 was a clear reflection of consistent execution, with double-digit growth across key markets in the US and Europe, and steady improvement in margins. Cenexi’s breakeven and strong revenue traction in the base business were key contributors to our consolidated performance this quarter.”
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Gland Pharma shares jump 9% after announcing Q3 results; Check details appeared first on Trade Brains.